Last Updated : July 16, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Received
Therapeutic Area:
Unresectable or metastatic MSI-H or dMMR solid tumors
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0377-000
Call for patient/clinician input closed:
Tumour Type:
Other
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab as
monotherapy for the treatment of adult and pediatric patients with unresectable
or metastatic microsatellite instability-high (MSI-H) or mismatch repair
deficient (dMMR) solid tumors, as determined by a validated test, that have
progressed following prior treatment and who have no
satisfactory alternative treatment options.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Pending
Indications:
Pembrolizumab as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 05-Jun-24 |
|---|---|
| Call for patient/clinician input closed | 26-Jul-24 |
| Submission received | 16-Jul-24 |
| Submission accepted | - |
Last Updated : July 16, 2024